PIEZO1 and breast carcinoma: Clinical breast cancer samples with Piezo1 high expression had fewer immunogenic characteristics, including the reduction of the activated CD4+ memory T cells and CD8+ T cells, which was associated with poor prognosis in breast cancer patients [27].